

The MorphoSys Share

During the 2010 fiscal year, MorphoSys's stock price increased by 9 %, outperforming the TecDAX index, which showed only a moderate annual growth of 4 %. The NASDAQ biotechnology index rose by 14 % in 2010.

KEY DATA FOR THE MORPHOSYS SHARE

(as of December 31 of each year)

		2010	2009	2008	2007	2006
Total Stockholders' Equity	In € million	185.9	173.9	162.0	145.5	100.1
Number of Shares Issued (Total)		22,890,252	22,660,557	22,478,787	22,160,259	20,145,996
Market Capitalization	In € million	424	386	421	357	365
Closing Price (Xetra)	€	18.53	17.04	18.75	16.10	18.12
Average Daily Trading Volume	In € million	1.1	1.3	1.9	2.5	1.9

The stock's performance benefited in particular from the acquisition of Sloning, the agreement with Pfizer and the multiple milestones that were reached in the final month of the year. Overall, the MorphoSys share price is beginning to reflect the Company's solid progress in building one of the most extensive antibody pipelines in the industry, together with a profitable and convincing business model.

LIQUIDITY AND INDEX MEMBERSHIP

The average daily trading volume of MorphoSys's stock was € 1.1 million per day, compared to an average trading volume of € 1.3 million per day in the previous year. MorphoSys consolidated its strong position in the TecDAX* index, which includes the 30 largest tech-

nology stocks on the Frankfurt Stock Exchange. At the end of 2010, the Company was able to improve its position based on **market capitalization*** to place 16 (year-end 2009: 17th place) and occupied 23rd position based on trading volume (year-end 2009: 19th position).

STOCKHOLDER BASE

The free float according to Deutsche Börse AG, which is generally taken into account in the weighting of MorphoSys's stock in stock indices, was 88 % of the share capital at year-end 2010.

Please visit our **website*** for the most recent information on investor relations.



THE MORPHOSYS SHARE

(January 4, 2010 = 100%)



SHAREHOLDER STRUCTURE

Shareholdings by Investor Type

(in %)

Institutional Investors


Retail Investors

Novartis

Management & Supervisory Boards

Treasury Stock

Unidentified Investors



Geographic Split of Institutional Holdings

(in %)

USA

Germany

UK

Switzerland

Belgium

Other European Countries

